1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO22468, 2009-012072-28, NCT01056510
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25137, NCT01283386
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TSH-WM1, ISRCTN56052618, TSH-WM1, NCT00608374
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WM1, NCT00566332
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 65 and ovr Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-CLL-008, Eudract #: 2008-003079-32, NCT00910910
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO21004, 2009-012476-28; CLL1, NCT01010061
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: RGN0117, NCT01657955
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: OMB114578, 2011-000919-22, 009988575, NCT01678430
|
|
9.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 to 65 Sponsor: Other Protocol IDs: CLL0709, NCT01403246
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MCL-002, NCT00875667
|
|
11.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115601, NCT01563055
|